A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity by de Oliveira, Bernardo L. & Niederer, Steven
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1371/journal.pcbi.1005214
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
de Oliveira, B., & Niederer, S. (2016). A Biophysical Systems Approach to Identifying the Pathways of Acute and
Chronic Doxorubicin Mitochondrial Cardiotoxicity. PL o S Computational Biology, 12(11), [e1005214].
10.1371/journal.pcbi.1005214
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
RESEARCH ARTICLE
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Identifying the Pathways of Acute and
Chronic Doxorubicin Mitochondrial
Cardiotoxicity
Bernardo L. de Oliveira, Steven Niederer*
Department of Biomedical Engineering, Division of Imaging Sciences and Biomedical Engineering, King’s
College London, London, United Kingdom
* steven.niederer@kcl.ac.uk
Abstract
The clinical use of the anthracycline doxorubicin is limited by its cardiotoxicity which is
associated with mitochondrial dysfunction. Redox cycling, mitochondrial DNA damage
and electron transport chain inhibition have been identified as potential mechanisms of
toxicity. However, the relative roles of each of these proposed mechanisms are still not
fully understood. The purpose of this study is to identify which of these pathways indepen-
dently or in combination are responsible for doxorubicin toxicity. A state of the art mathe-
matical model of the mitochondria including the citric acid cycle, electron transport chain
and ROS production and scavenging systems was extended by incorporating a novel
representation for mitochondrial DNA damage and repair. In silico experiments were per-
formed to quantify the contributions of each of the toxicity mechanisms to mitochondrial
dysfunction during the acute and chronic stages of toxicity. Simulations predict that redox
cycling has a minor role in doxorubicin cardiotoxicity. Electron transport chain inhibition is
the main pathway for acute toxicity for supratherapeutic doses, being lethal at mitochon-
drial concentrations higher than 200μM. Direct mitochondrial DNA damage is the principal
pathway of chronic cardiotoxicity for therapeutic doses, leading to a progressive and irre-
versible long term mitochondrial dysfunction.
Author Summary
Doxorubicin is a potent anticancer drug, but its efficacy is limited by a cumulative dose-
dependent cardiotoxicity. Multiple pathways are involved in the drug cardiotoxicity, how-
ever, the underlying mechanisms are still not fully elucidated. Here we developed a
computational model to study doxorubicin mitochondrial cardiotoxicity, which allowed
for the first time, a systematic test of different hypothesis in a unified framework. By quan-
titatively comparing the effect of multiple toxicity mechanisms, we could identify that
electron transport chain is the main cause of acute toxicity, while direct damage to the
mitochondrial DNA is the principal pathway of chronic cardiotoxicity. This is a crucial
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step in developing new antitumor therapies, toxicity screens and developing treatments to
mitigate doxorubicin cardiotoxicity.
Introduction
Doxorubicin (DOX) is an anthracycline antibiotic with potent antineoplastic properties [1]. It
has a broad-spectrum and is widely prescribed in the treatment of many types of cancers,
including solid tumors and leukemias [2]. Yet, the clinical use of this drug is restricted by its
severe side effects. DOX presents dose dependent, cumulative and irreversible cardiotoxicity
that can lead to cardiomyopathy and ultimately congestive heart failure [3]. However, the
underlying biochemical mechanisms of its toxicity are still not fully elucidated.
Different processes are involved in DOX cardiotoxicity, including apoptosis, intracellular
calcium dysregulation and myofibrillar detereoration, among others [4]. DOX cardiotoxicity
is also strongly associated to mitochondrial dysfunction that leads to increased reactive oxygen
species (ROS) production and cardiac oxidative stress [5]. DOX can inhibit the electron trans-
port chain (ETC) by binding to cardiolipin which is present in the inner mitochondrial mem-
brane [6]. As cardiolipin is required for normal ETC activity, this interaction leads to ETC
inhibition [7]. During acute exposure, DOX also increases ROS production by undergoing
redox cycling. The drug is capable of oxidising Complex I of the ETC, stealing electrons and
transfering them directly to oxygen, producing ROS [8]. Furthermore, DOX acts as a topo-
isomerase II poison [9] and can form DNA adducts [10], which can damage the DNA and
inhibit gene transcription and DNA replication [11–14].
It has been suggested that these interactions can form vicious cycles that could continue
operating even after the termination of the treatment, accumulating over time, and ultimately
leading to bioenergetic failure [15]. DOX can potentially influence all elements of these cycles
as depicted in Fig 1 where two possible vicious cycles can be observed. Vicious cycle one
involves increased ROS levels which can inactivate the ETC and cause a further increase in
ROS production. In vicious cycle two, increased ROS levels cause mtDNA damage which can
lead to a downregulation of the ETC proteins that are mtDNA encoded, exacerbating mito-
chondrial dysfunction and ROS production.
The objective of this study is to test the hypothesis that such vicious cycles could be formed
by developing a computational model that quantitatively links alterations in ETC activity, ROS
production and mtDNA damage with mitochondrial dysfunction. The goal is to quantify the
contributions of each of these different toxicity pathways and possible vicious cycles to mito-
chondrial dysfunction associated with acute and chronic DOX cardiotoxicity.
Results
Acute Effect
To quantify the relevance of vicious cycle one depicted in Fig 1, the acute effects of DOX were
initially studied taking only ETC inhibition and redox cycling into account. This allowed us to
investigate these two mechanisms in isolation and combined, prior to accounting for mtDNA
damage.
The predicted acute effects of redox cycling and ETC inhibiton at different concentrations
of DOX can be observed in Fig 2. This experiment consisted of introducing a constant concen-
tration of the drug and performing a simulation until the model reached a steady state. This
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allowed us to quantify how mitochondrial function varies in the presence of different concen-
trations of the drug.
Across all simulations we can observe similar features. For low drug concentrations, the
ATP concentration and the membrane potential were only barely reduced, with an associated
increase in the O2 consumption and concentrations of [•OH], ½O: 2  and [H2O2]. We can also
observe that, for concentrations of up to 160μM, redox cycling is the main contributor for the
increase in ROS, while for concentrations higher than that, the effect of ETC inhibition
becomes dominant. For high drug concentrations, mitochondrial function gradually deterio-
rate until a threshold is reached and the mitochondria completely collapse. This causes a com-
plete loss of membrane potential and ATP concentration, a sharp increase in the ROS
concentrations and a reduction in the O2 consumption to residual levels, indicating that the
dose may be lethal. This threshold happened at 480μM in the simulations including redox
cycling only, 270 μM taking only ETC inhibition into account and 210 μM taking both into
account.
A series of dynamic simulations were performed to investigate if ETC inhibition and redox
cycling could lead to any permanent alteration in mitochondrial function by forcing the mito-
chondria into a new steady state. In these simulations, time varying concentrations of DOX
were used as an input to the model, respecting the drug pharmacokinectics. A fast absorption
of the drug was assumed with half-time of 5 minutes while the elimination of the drug was
considered to be slower with a half-time of 24 hours [16] as depicted in Fig 3. Four suprathera-
peuthic doses were tested spanning a range of concentrations lower than the lethal dose of 210
μM, that was predicted from the simulations presented in Fig 2. For low doses, mitochondrial
function is only marginally affected, but at high doses, some significant variations can be
observed. Mitochondrial function deteriorates as the dose increases, with a decrease in ATP
concentration, membrane potential and NADH levels and an increase in ROS concentrations
and O2 consumption. Additional simulations revealed that decreases in both the membrane
Fig 1. DOX could trigger vicious cycles that lead to progressive mitochondrial dysfunction. The
dashed arrows represent the acute effects of DOX. The solid arrows represent the interactions between
elements while the gray arrows represent the potential vicious cycles that could be formed.
doi:10.1371/journal.pcbi.1005214.g001
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potential and matrix pH equally contribute to an alteration in Complex IV activity which
results in the increased O2 consumption observed. In all the dynamic simualtions, these effects
are always temporary and all quantities return to their baseline values after the drug is fully
eliminated from the system. This indicates that ETC inhibition and redox cycling, and thus the
possible vicious cycle one in Fig 1, are not sufficient to explain long term mitochondrial dys-
function associated with DOX.
Chronic Effect
As our model including redox cycling and ETC inhibition was not capable of reproducing any
permanent and long term alteration in mitochondrial function, the mtDNA model repre-
sented in Eq 1 was introduced to investigate if mtDNA damage, and vicious cycle two in Fig 1,
could explain the chronic toxicity of DOX.
Fig 2. Normalized variation of different indices of mitochondrial function with respect to acute concentrations of
DOX in the mitochondria. A constant concentration of DOX was used as an input and simulations were performed until
steady state. It is possible to compare the effects of ETC inhibition, redox cycling (RC) and both combined.
doi:10.1371/journal.pcbi.1005214.g002
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Prior to investigating the damaging effects of DOX to the mtDNA, we performed simula-
tions to evaluate how mitochondrial function is affected by variations in the mtDNA content
without including any DOX effect. In our model, as the mtDNA content is altered, the expres-
sion of all proteins and enzymes encoded by it are scaled, namely, Complexes I, III, IV and
ATP synthase. In order to generate a phase plot and to predict the dependency of mitochon-
drial function on the mtDNA content, multiple experiments were performed by holding the
mtDNA content constant at different values and simulating until a new steady state was
achieved. The results of these simualtions can be seen in Fig 4. We can observe that at baseline
conditions with a mtDNA content of 0.75, its time derivative, dmtDNA/dt, is equal to zero, in a
stable condition with all the indices of mitochondrial function also at baseline.
For mtDNA contents higher than baseline, no significant improvement in mitochondrial
function is observed and dmtDNA/dt is negative. This is caused by an attenuation of the
mtDNA repair activity such that intrinsic ROS production causes enough damage to mtDNA
to reduce its content to baseline conditions over time.
For mtDNA contents lower than baseline, dmtDNA/dt has a biphasic behaviour with a posi-
tive and a negative region. A stable region is observed for mtDNA contents between 0.75 and
0.73. In this region, dmtDNA/dt is positive, as the mtDNA repair activity is greater than the
Fig 3. Normalized dynamic variation of mitochondrial function to different doses of DOX. Time varying concentrations
of DOX following the drug’s pharmacokinetics were used as an input. The resulting variation in different measurements of
mitochondrial function can be observed.
doi:10.1371/journal.pcbi.1005214.g003
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mtDNA damage caused by ROS, causing the mtDNA content to recover back to baseline. An
unstable region is observed for mtDNA contents lower that 0.73. In this region, dmtDNA/dt is
negative, as the increased ROS concentrations generate more mtDNA damage than the
mtDNA repair system can handle. This indicates that 0.73 is a bifurcation point that is a
threshold of how much mtDNA damage a mitochondrion can recover from. Any reduction in
mtDNA content below 0.73 leads to a perpetuating and progressive decrease in mitochondrial
function.
It is also possible to observe that reductions in the mtDNA content also lead to an increase
in the O: 
2
concentration. As the mtDNA content is reduced, O: 
2
production by Complex I is
reduced, but a concomitant increase in O: 
2
production by Complex III is observed and the
combined O: 
2
production monotonically increases. The superoxide production by Complex
III is increased as a reduction in the density of this complex leads to a reduction in the rate of
the reactions involved in the Q-cycle. This causes changes in the concentrations of the sub-
strates involved in these reactions, including an increase in the semiquinone radical ion con-
centration. This increase in the semiquinone radical ion concentration consequently leads to
an increase in the rate that this radical is oxidized by O2, which is the source of O: 2 production
by Complex III.
Fig 4. Effects of the variation of the mtDNA content in mitochondrial function. It is possible to observe a
bifurcation point when the mtDNA content is equal to 0.73. For mtDNA contents higher than 0.73 the mitochondria are
in a stable condition and recovers to baseline over time. For a mtDNA content lower than 0.73, the mitochondria are
unstable and its function will perpetually deteriorate until collapse.
doi:10.1371/journal.pcbi.1005214.g004
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Fig 5 shows the model predictions for how mitochondria function is affected over time by
different numbers of weekly doses of 1mg/kg of DOX, which are equivalent to doses of 30μM
in our model. The red errorbars in the first panel are the experimental data points used to fit
the model parameters [15], and are related to in vivo measurements of mtDNA content after
seven weekly doses of DOX in rats. With only one dose, we can already observe long term
alterations in mitochondrial function, however, the mtDNA content is only slightly reduced
and the mitochondria manage to recover through mtDNA repair. With four doses the damage
is already large enough to trigger a vicious cycle, but the progression of the mitochondrial dys-
function is slow as the damage is relatively small and may not lead to observable symptoms.
With seven doses and more, the damage is significant, triggering a fast degradation of mito-
chondrial function. We can observe a progressive reduction in the mtDNA content and ATP
Fig 5. Predicted effects of the treatment with weekly doses of 30μM of DOX. One dose is not sufficient to trigger the
vicious cycle responsible for chronic cardiotoxicity. With four doses, the vicious cycle is triggered but the progression is
slow. With seven doses, a faster progression is observed and the predicted reduction in mtDNA content is within the error
of the experimental data used to fit the model’s parameters [15]. With ten doses a fast deterioration and collapse in
mitochondrial function is observed.
doi:10.1371/journal.pcbi.1005214.g005
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concentrations and an increase in ROS levels. The spikes observed in the curves are related to
the DOX doses that have a peak while the drug is still in the system, but keeps a cumulative
dysfunction even after the drug is eliminated due to the mtDNA damage. Our model also pre-
dicts that direct mtDNA damage by DOX is the main pathway that triggers this vicious cycle,
being responsible for over 75% of the mtDNA content reduction during the acute stages of
DOX intoxication.
Cardioprotection Simulation
Free iron plays an important role in modulating DOX cardiotoxicity by serving as a catalyst to
the formation of hydroxyl radicals through the Haber-Weiss reaction [17]. Iron chelators have
demonstrated cardioprotection properties when co-administred with DOX as they bind to
iron and eliminate this heavy metal from the body [18, 19]. More specifically, co-administra-
tion of Dexrazoxane with DOX has been shown to prevent a rise in free iron levels observed
when administring DOX in isolation, reverting this cardiotoxic effect and keeping the the free
iron levels at baseline [20].
Co-administration of Dexrazoxane has also been shown to mitigate mtDNA damage and
the loss of mtDNA content associated with DOX [21]. To test if our model is capable of captur-
ing this protective property, we used a simplified model of chelating therapy by assuming that
the free iron levels are kept constant at baseline during chelating treatment [20]. A detailed
description can be found in the supplemental material. Our simulations reproduced the setup
of this in vivo experiment where seven weekly doses of 0.8 mg/kg of DOX, which are equiva-
lent to doses of 24μM in our model, were administred in rats, with and without the co-admin-
istration of iron chelators, and the mtDNA content was measured 37 weeks after the
termination of the treatment [21]. Fig 6 shows the variation in the mtDNA content observed
Fig 6. Predicted effects of the treatment with seven weekly doses of 24μM of DOX with and without
co-treatment with iron chelators. In the simulation without iron chelator co-treatment (blue), the predicted
reduction in the mtDNA content agrees with the experimental data, which was used in the fitting of the model’s
parameters [21]. The model was capable of capturing the cardioprotective feature of iron chelator co-
treatment (green), and the predicted reduction in the mtDNA content also agrees with experimental data [21].
The model predicts that extending the iron chelation therapy by double (red) or triple (yellow) the duration of
the DOX treatment can enhance cardioprotection.
doi:10.1371/journal.pcbi.1005214.g006
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in these simulations, while the errorbars are the mtDNA content measured in the in vivo
experiment. We can see that our model was able to capture the protective properties of the che-
lating therapy, although to a lesser extent than the ones observed in vivo. Our model also pre-
dicts that extending the chelating treatment to two of three times the duration of the DOX
treatment might considerably increase the cardioprotection offered by further decreasing the
loss of mtDNA content.
Discussion
In this work, a biophysical model of the mitochondria was adapted to represent the cardiotoxic
effects of DOX. Computational models have already been used to study mitochondrial dys-
function [22], ROS generation [23, 24] and ROS scavenging [25, 26]. However, this is the first
time, that this kind of models has been used to study drug cardiotoxicity.
Three pathways of DOX cardiotoxicity were modeled, with all parameters constrained
using experimental data, and their contributions to mitochondrial dysfunction were quanti-
fied. Our model predicts that although redox cycling is the main contributor to acute increases
in ROS concentrations at clinically relevant concentrations, of approximatelly 30μM [16], it
has a minor role in DOX cardiotoxicity as any considerable loss of mitochondrial function can
only be obeserved at much higher concentrations, as observed in Fig 2. ETC inhibition also
showed negligible effects at clinically relevant concentrations, however, when a critical mito-
chondrial concentration of 210 μM is reached, it is the principal mechanism for a sharp and
rapid collapse in mitochondrial function. For doses higher than this critial concentration, the
mitochondria are not able to sustain the membrane potential, which causes a collapse in mito-
chonrial function and depletion of ATP. These results are in agreement with experiments
where mice treated with a single 15mg/kg dose of DOX, which correspond to a dose of 450μM
in our model, were used to test the hypothesis of redox cycling mediated cardiotoxicity [14].
This experiment showed a reduction in ETC activity and a rapid depletion of ATP, followed
by a decrease in the expression of myocardial ETC genes.
Our results also showed that redox cycling and ETC inhibition alone are not capable of gen-
erating any long term alterations in mitochondria function, as depicted in Fig 3. The chronic
cardiotoxicity of DOX was only reproducible when taking mtDNA damage into account,
which was necessary and sufficient to trigger a vicious cycle that leads to a progressive loss of
mitochondrial function. These findings highlight the importance of dosing for in vivo and in
vitro experiments when investigating DOX cardiotoxicity as the dominant toxicity pathways
of acute therapeuthic dosing, acute supratherapeuthic dosing and chronic therapeuthic dosing
could be different.
To study chronic DOX toxicity, a novel mtDNA damage and repair model was proposed,
including the subsequent alterations in the expression of mtDNA encoded proteins that was fit
to experimental data [15]. This model was capable of reproducing the cumulative and progres-
sive long-term effects of DOX toxicity in the time course of weeks and even years. We observed
that the effect of a single clinical dose is not sufficient to lead to progressive mitochondrial dys-
function as the mitochondria manage to recover. However, mtDNA damage accumulates after
sucessive doses and vicious cycle 2 depicted in Fig 1 is triggered. With mtDNA damage, the
expression of mtDNA encoded proteins is reduced, leading to progressive mitochondria dys-
function until bioenergetic failure. As observed in Fig 4, a mtDNA content reduction of
approximately 5% with respect to baseline is enough to trigger a vicious cycle by moving mito-
chondria function from a stable to an unstable state.
The assumptions made in the model, related to •OH production, potentially overestimate
oxidative mtDNA damage (see section S3 of the supplemental material for details), however,
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this is unlikely to alter the study conclusions as we identified direct damage to mtDNA by
DOX as the main pathway to trigger the vicious cycle responsible for DOX chronic cardiotoxi-
city. It was quantified that direct mtDNA damage by DOX is responsible for over 75% of the
mtDNA content reduction during the acute stages of intoxication. Although oxidative
mtDNA damage by ROS has a secondary role during the acute stages, it allows this vicious
cycle to be sustained after the chemotherapy treatment is completed and the drug has been
eliminated. These results are in agreement with experiments that showed that cardiomyocite
specific deletion of the gene encoding topoisomerase-IIβ, involved in mtDNA damage by
DOX, protects cardiomyocytes from doxorubicin induced defective mitochondria and ROS
formation [9], while co-administration of ROS scavengers and antioxidants failed to prevent
cardiac toxicity both experimentally [27] and clinically [28].
The only approved cardioprotective agent that has shown efficacy when co-administred
with DOX in clinical settings is the iron chelator Dexrazoxane [28, 29]. Our model was capable
of capturing this protective property of iron chelator co-administration, which reduces the ini-
tial insult to mtDNA, as shown in Fig 6. However, this protection is partial, not only because
mtDNA damage by ROS has a secondary role during the acute stages, but also because, even
when the iron levels are kept at baseline, an increase in the hydroxyl concentration and
mtDNA damage by ROS is still observed as a consequence of increased peroxide concentra-
tions. The model predicts that extending the iron chelating therapy to time periods longer
than the DOX treatment can enhance this protective property. This generates a longer time
period with reduced oxidative damage to mtDNA by ROS, allowing the mitochondria to repair
more of the initial damage, potentially reverting the vicious cycle or at least slowing down the
progression of dysfunction.
All models are inherently simplifications and aim to represent the salient features of the
underlying system. Here we discuss the limiations and assumptions of the models and the
potential impact on the study conclusions. The repair systems of mtDNA are complex and still
poorly understood, with mulitple mechanisms reported in the literature [30]. Due to the spar-
sity of experimental data available, a simplified model was adopted, with all mtDNA repair
activity lumped into a single enzymatic term. Also, due to the limited data to constrain the
model’s parameters, an additional 15,000 simulations were performed, exhaustively exploring
the space of potential parameter combinations, to test if the study results were dependent on
the specific parameter set evaluated. All of the evaluated parameter combinations, that gener-
ated results within the errorbars of the experimental data, support the conclusion that direct
damage to mtDNA by DOX is the main toxicity pathway responsible for triggering the vicious
cycle that leads to mitochondrial dysfunction. More details can be found in section S3 of the
supplemental material.
In the model, the expression of mtDNA encoded proteins was considered to be propor-
tional to the mtDNA content. Although these quantities are correlated, there could be delays
between the mtDNA damage and the reduction in the density of mtDNA encoded proteins,
and this could play a role especially during the initial stages of the cardiotoxicity. Also,
although redox cycling and oxidative damage to mtDNA are represented in our model, we do
not take into account oxidative damage to any other structures or proteins. It is possible that
the damage caused by the elevated ROS levels to other structures contributes to DOX cardio-
toxicity. This may effect proteins, lipids and other pathways not represented in this model,
including calcium dysregulation [31] and mitochondrial permeability transition [32]. It has
also been proposed that DOX removes proginator cells that may contribute to a heart failure
phenotype [33]. These may be contributing factors, however, the observed increase in ROS
production and decrease in mtDNA content are consistent with the mitochondria playing a
prominent role in DOX cardiotoxicity.
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Despite these limitations, this work presents a computational model for DOX mitochon-
drial cardiotoxicity that gives new insights into the drug’s toxicity mechanisms and cardiopro-
tection alternatives and allows us to combine and evaluate multiple hypothesis concurrently
within a common framework. The models developed here can be further used to test different
DOX treatment protocols, cardioprotection strategies or to study the cardiotoxicity of other
drugs. The framework of this study and the novel mtDNA damage and repair model developed
here have applications even beyond drug cardiotoxicity, as mitochondrial dysfunction and
mtDNA damage are associated with multiple other pathologies and applications such as heart
failure [34], cardiac and cerebral ischemia reperfusion injury [35, 36] and aging [37].
Models
A detailed biophysical computational model of the mitochondria was adapted to simulate the
effects of DOX. The original model [38] incorporates, in a unified framework, all the major
components for the study of DOX mitochondrial cardiotoxicity: the TCA cycle, transporters,
ROS production and scavenging systems and a detailed ETC representation [39]. All simulations
in this work consider that the mitochondria are in the presence of substrate and ADP (state 3
respiration), and results are normalized with respect to baseline conditions, which were calcu-
lated by simulating the mitochondria in the absence of DOX until steady state. The acute effects
of DOX depicted in Fig 1 were modeled and incorporated into the biophysical mitochondria
model, shown in Fig 7, where the acute DOX effects are highlighted in red. This section will
briefly descibe how each these toxic pathways were modeled. A full description of all the model’s
equations, parameters and constants adopted can be found in the supplemental material.
ETC Inhibition
When present in the mitochondria, DOX binds onto cardiolipin in the mitochondrial mem-
brane which in turn inhibits the complexes of the ETC. The activity of each of the four ETC
complexes has been recorded in isolation at multiple concentrations of DOX, and the IC50 val-
ues have been reported in the literature [7]. In our model, this data along with corresponding
fitted Hill coefficients, were used to construct dose dependent functions to scale the activity of
each of the ETC complexes. More details can be found in section S1 of the supplemental
material.
Redox Cycling
Increased ROS production by redox cycling was represented by augmenting superoxide pro-
duction by Complex I, which has been identified as the redox cycling site for DOX [8]. This
increase in superoxide production was considered to be proportional to the concentration of
the drug and fitted to experimental data [15]. In this experiment, a 7% increase in the superox-
ide concentration was measured two hours after the administration of 1mg/kg of DOX in rats.
In humans, this dose is equivalent to a clinically relevant concentration of 37mg/m2 [40] which
generate mitochondrial concentrations in the range of 5 to 30μM [16]. In this study, the redox
cycling parameters were manually adjusted to generate a similar 7% increase in the superoxide
concentration for a DOX dose of 10μM. More details can be found in section S2 of the supple-
mental material.
Damage to mtDNA
To take into account the damaging effects of DOX in the mtDNA, we propose a new mass
action model for mtDNA damage and repair. This model includes a variable for the mtDNA
Identifying the Pathways of Doxorubicin Mitochondrial Cardiotoxicity
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content, which was considered unitless and normalized. At baseline conditions the damaging
term is equal to the repair term, keeping the mtDNA content constant at 0.75 [41, 42]. The
expression of all proteins and enzymes encoded in mtDNA was considered to be scaled by the
mtDNA concentration. More specifically, Complexes I, III, IV and ATP synthase have their
expression and protein densities scaled by the mtDNA content. We consider that when
mtDNA is damaged, its content is reduced and if mtDNA is repaired, its content is increased
as represented in Eq 1:
dðmtDNAÞ
dt
¼ a 
ð1   mtDNAÞ
ð1   mtDNAÞ þ k
 
  b  ½OHn mtDNA   g½DOX mtDNA: ð1Þ
Where α is the mtDNA repair maximum rate, κ is the mtDNA repair half-saturation coeffi-
cient, β is the coefficient for mtDNA damage by ROS, [•OH]n is the normalized hydroxil radi-
cal concentration and γ is the coefficient for mtDNA damage by DOX. The first term of the
equation represents the mtDNA repair system. As the mtDNA repair activity is conducted by
enzymes, this term was considered to have an assymptotic behaviour [30, 43]. If the mtDNA is
damaged and its content is decreased, the repair activity increases until a saturation is achieved
Fig 7. A schematic of the mitochondrial model used. The expressions of ATP synthase and Complexes I, III and IV of the ETC are scaled by the
mtDNA content as these structures are encoded at mtDNA. The acute effects of DOX are highlighted in red.
doi:10.1371/journal.pcbi.1005214.g007
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where the system is working at full power. The second term represents mtDNA damage by
[•OH] which is a ROS capable of damaging DNA [44]. This highly reactive oxidant has been
shown to be produced in biological systems through iron-catalyzed Haber-Weiss reaction,
which make use of Fenton chemistry [45]. If [•OH] levels rise above baseline conditions, the
mtDNA damaged rate is increased and its content reduced. The third and last term represents
direct damage to the mtDNA by DOX and was considered to be proportional to the mtDNA
content and the drug concentration. The model parameters were fitted using data from in vivo
experiments [15, 21] where mtDNA content reductions were measured after treating rats with
seven weekly doses of DOX. An extended description of the model’s assumptions, parameters
fitting and sensitivities can be found in section S3 of the supplemental material.
Supporting Information
S1 Text. Supplementary information and figures. This document contains all the supple-
mentary information and figures associated with the main text.
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